23 February 2018 | News
Children 6 months through 35 months of age are particularly vulnerable to the flu, and the efficacy results from this trial are promising
GSK presented at the Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices meeting that FLUARIX® QUADRIVALENT demonstrated 63.2% efficacy against moderate to severe influenza and 49.8% efficacy against influenza of any severity in children 6 months through 35 months of age.
These results are based on a randomized, observer-blind, non-influenza vaccine-controlled trial that enrolled 12,018 children in five independent cohorts in 13 countries in Asia, Europe, and Central America from 2011 through the end of 2014.
FLUARIX® QUADRIVALENT was immunogenic against all four vaccine strains (i.e., A/H1N1, A/H3N2, B/Victoria and B/Yamagata).
The safety and reactogenicity profile was similar to vaccines used in the same age group. No safety signal was observed.
Additionally, the study found that FLUARIX® QUADRIVALENT reduced healthcare utilization (i.e., antibiotic use, general practitioner visits and emergency department visits) related to confirmed influenza illness.